SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDVO.L Regulatory News (DVO)

  • There is currently no data for DVO

Trading Update

10 Nov 2016 07:00

RNS Number : 8050O
Devro PLC
10 November 2016
 

This announcement contains inside information

10 November 2016

 

Devro plc

 

Trading Update

 

Devro plc ("the Group"), one of the world's leading manufacturers of collagen products for the food industry, today issues a trading update for the period 1 July 2016 to the current date ("the period").

Trading summary for the period and 2016 outlook

Sales volume trends were broadly similar to those experienced in the first half, enhanced by improvements in Russia and South East Asia, but impacted by further reductions in Latin America due to the previously highlighted issues, which are being addressed, related to the transformation of our global manufacturing footprint. Combined, these factors have had an adverse impact on margins, offset by further benefits from lower input costs and foreign exchange. As a result, the Board's full year expectations for underlying operating profit* remain unchanged.

Our new factories in the US and China are now integrated into the Group's manufacturing base, completing the transformation of our global manufacturing footprint. As expected, in the second half £8 million of exceptional costs related to these capital investment projects have been incurred, including £1 million of additional foreign exchange movements. There will be no further exceptional costs related to these capital investment projects.

2017 and beyond

Based on current trends, sales volumes in 2017 are now expected to be approximately 10% lower than previously anticipated, which will result in an under-utilisation of available capacity. Actions are being taken to rebalance the use of capacity across our global manufacturing base. The under-utilisation is expected to have a further adverse impact on margins.

The Board has decided to accelerate and implement more extensively the next stage of the Group's strategic development, focusing on growing sales through improved commercial capabilities, introducing the next generation of differentiated products, and further improving manufacturing efficiencies to reduce unit costs. This improvement project will deliver a fundamentally more competitive position. The benefits will offset the effects of the lower volumes, partially in 2017 and fully in 2018. 

Consequently, the Board now expects underlying operating profit* for 2017 to be lower than previous expectations.

There will be additional costs and capital expenditure associated with the improvement project. Given the nature and scale of the planned actions, these costs will be charged as exceptional items, of which approximately £3 million is expected to be incurred in the final quarter of 2016.

Devro's markets remain attractive. With completion of the capital investment projects the Group now has an excellent manufacturing base and, with the benefits resulting from the improvement project, the Board considers the Group to be well positioned to grow revenue and profits over the long term.

* Underlying operating profit is defined as operating profit before exceptional items

 

ENDS

 

 

Contacts:

 

Devro plc

Peter Page

Chief Executive

Tel: 020 7182 4960

Rutger Helbing

Group Finance Director

Tel: 020 7182 4960

 

FTI Consulting

Richard Mountain / Nick Hasell

Tel: 020 3727 1340

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFSIEFUFMSEDF
Date   Source Headline
13th Sep 20183:23 pmRNSHolding(s) in Company
3rd Sep 20184:44 pmRNSHolding(s) in Company
9th Aug 20181:48 pmRNSDirector/PDMR Shareholding
9th Aug 20181:45 pmRNSDirector/PDMR Shareholding
1st Aug 20184:55 pmRNSHolding(s) in Company
1st Aug 20187:00 amRNSHalf Year Results
9th Jul 20184:30 pmRNSHolding(s) in Company
4th Jul 20183:58 pmRNSHolding(s) in Company
4th Jun 20183:19 pmRNSHolding(s) in Company
16th May 20182:47 pmRNSHolding(s) in Company
15th May 20183:11 pmRNSDirector/PDMR Shareholding
14th May 20184:46 pmRNSDirector/PDMR Shareholding
8th May 20182:30 pmRNSHolding(s) in Company
4th May 201810:41 amRNSHolding(s) in Company
30th Apr 20183:28 pmRNSDirector/PDMR Shareholding
25th Apr 20184:49 pmRNSAGM - VOTING RESULTS
25th Apr 20187:00 amRNSTrading Update
19th Apr 20183:38 pmRNSHolding(s) in Company
10th Apr 201811:11 amRNSDirector/PDMR Shareholding
9th Apr 20184:00 pmRNSDirector/PDMR Shareholding
3rd Apr 20187:06 amRNSDirector Declaration
29th Mar 20181:00 pmRNSAppointment of Chief Financial Officer
23rd Mar 20184:00 pmRNS2017 Annual Report and Notice of AGM
28th Feb 201811:28 amRNSDirector/PDMR Shareholding
28th Feb 20187:00 amRNSDirectorate change confirmation
27th Feb 20187:00 amRNSRESULTS FOR THE YEAR ENDED 31 DECEMBER 2017
7th Feb 20184:52 pmRNSHolding(s) in Company
12th Jan 20184:08 pmRNSHolding(s) in Company
5th Jan 20184:54 pmRNSHolding(s) in Company
19th Dec 20172:26 pmRNSHolding(s) in Company
19th Dec 20179:20 amRNSHolding(s) in Company
18th Dec 20174:33 pmRNSHolding(s) in Company
11th Dec 20173:02 pmRNSDirector/PDMR Shareholding
11th Dec 20177:00 amRNSDirectorate Change
9th Nov 20177:00 amRNSTrading Update
26th Oct 201712:20 pmRNSDirector/PDMR Shareholding
18th Aug 20174:18 pmRNSHolding(s) in Company
17th Aug 20175:03 pmRNSHolding(s) in Company
8th Aug 201710:35 amRNSHolding(s) in Company
2nd Aug 20174:54 pmRNSDirector/PDMR Shareholding
2nd Aug 20174:46 pmRNSDirector/PDMR Shareholding
2nd Aug 20174:45 pmRNSDirector/PDMR Shareholding
2nd Aug 20177:00 amRNSDevro plc Half Year Results 2017
23rd Jun 201710:03 amRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
30th May 201711:01 amRNSBlock Listing Six Monthly Return
16th May 20172:38 pmRNSHolding(s) in Company
26th Apr 20175:15 pmRNSResult of AGM
26th Apr 20177:00 amRNSTrading Update
20th Apr 20178:32 amRNSHolding(s) in Company
11th Apr 20174:12 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.